SOURCE: Marathon Patent Group, Inc.

Marathon Patent Group, Inc.

January 06, 2015 09:00 ET

Marathon Patent Group Announces That the USPTO Has Denied Texas Instruments Inc. Petition for Inter Partes Review of Vantage Point Patent

LOS ANGELES, CA--(Marketwired - Jan 6, 2015) - Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon"), a patent licensing company, announced today that on January 5, 2015, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Texas Instruments Inc. against Marathon subsidiary Vantage Point Technology's U.S. Patent No. 5,463,750 ('750 patent).

The PTAB ruled: "We determine that the record before us does not demonstrate that there is a reasonable likelihood, under 35 U.S.C. § 314(a) that Petitioner would prevail with respect to at least one challenged claim. We consequently deny the Petition and decline to institute inter partes review of the '750 patent."

"We are pleased with the USPTO's decision denying Texas Instruments Inc.'s IPR petition," said Doug Croxall, Founder and CEO of Marathon Patent Group. "We will continue to seek reasonable royalty payments from those who infringe the '750 patent. Hopefully the IPR denial will encourage the parties in suit to reach reasonable licensing arrangements with Vantage Point."

About Marathon Patent Group:
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.

Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information